Clinuvel compared to Imugene, page-24

Yep $40 Million full year profit looks to be a lock so that means EPS = 0.81 AUD (conservative forecast)

This in turn means at a share price of $40 CUV will have a P/E less than 50!

This is amazing when other peer biotechs have theoretically infinite P/Es based on their pipeline and greater market cap.s than CUV and it means Clinuvel has $0 valuation given to their own amazing R&D pipeline when they are using an already FDA, TGA, EMA approved drug for that pipeline? It also means Clinuvel is being given a P/E ratio similar to CSL or COH who are not growing at anything like the rate of CUV.

And the main reason the CUV price is so low right now is simply that it is the 28th most shorted stock on the ASX - (fake liquidity on the Sell side). This makes completely no sense when they are growing revenue/profits over 50% easily and have zero debt and zero chance of going broke and they have an absolute market monopoly for years to come in the EPP space! The good thing is that these open short positions have to be bought back and good luck buying 2.5 Million CUV shares.

Without the attention of short sellers this would easily be sitting at $40- $50 which is well within historical P/Es. Market analysts will catch up eventually after it all plays out. Wish I had a spare million to throw in at these levels, might even sell a rental to do just that but I think the half yearly in about 3 weeks will spark some upgrades and interest.

All IMO DYOR